Valbiotis is intensifying its presence in the Asian market

The French laboratory Valbiotis, specializing in dietary supplements, continues its expansion in Asia. Through its Chinese joint venture, Hangzhou Valbiotis Life Health Technology, the company recently inaugurated a subsidiary in Singapore. This step marks the beginning of its expansion beyond China and Hong Kong, where it is already active.

The Singaporean subsidiary plans to enter several key markets, including Singapore, Vietnam, Indonesia, and Japan. To achieve this, Valbiotis will leverage e-commerce channels and traditional distribution networks. The first sales targeting the Asian market are expected in the second half of 2026.

With its partner Aika, Valbiotis aims to become a leading player in the prevention of cardiometabolic imbalances through natural solutions. In China, the products will be distributed via cross-border e-commerce, a rapidly growing sector.